Porter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776.

One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.

NanoViricides (NYSE: NNVC) just received FDA Orphan Drug Designation for NV-387 as a measles treatment, unlocking seven years of market exclusivity and reduced regulatory costs.

NV-387 is built on a nanoviricide platform designed to neutralize viruses before cell infection - targeting multiple viruses with a single approach. With Phase I safety data complete and Phase II trials advancing, NNVC is moving from early-stage concept to catalyst-driven story at a time when measles resurgence is exposing a clear gap in antiviral treatment options.

Tim Sykes spent over $1 million developing a patent-pending AI forecasting tool built to spot explosive one-day moves before they happen. Over the last 12 months, its forecasts led to peak one-day gains above 100% on 40 separate occasions - 20 of those topped 200%.

Wall Street banks keep tools like this behind closed doors. JPMorgan alone has 2,000-plus data scientists building theirs. For a limited Fourth of July window, Tim is opening access to his for $1.